University of Mary Hardin-Baylor

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, University of Mary Hardin-Baylor sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 8 completed top decile by trial count

University of Mary Hardin-Baylor: 10 sponsored US clinical trials, none currently recruiting.

University of Mary Hardin-Baylor sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. The most-studied condition in this pipeline is Evaluation of Bioavailability of Supplemental Forms of Iron, with 1 trials.

Top-decile sponsor footprint

University of Mary Hardin-Baylor ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

How the University of Mary Hardin-Baylor archive is shaped

10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Evaluation of Bioavailability of Supplemental Forms of Iron (1 trial), 8 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

University of Mary Hardin-Baylor: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

University of Mary Hardin-Baylor sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share University of Mary Hardin-BaylorAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
University of Mary Hardin-Baylor sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Mary Hardin-Baylor sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

What to do with this University of Mary Hardin-Baylor page

10 registered trials is a research-attention snapshot, not an endorsement of University of Mary Hardin-Baylor or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Mary Hardin-Baylor pipeline card: 10 registered trials from official public datasets.Report a data error.